Steven Curley, MD
Basic profileThe University of Texas MD Anderson Cancer Center
Steven Curley is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 22 publications with 2,114 citations (h-index 15); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
910 E Houston St Ste 270
Tyler, TX 757028367
Telephone
903-606-4300Registry record last updated 1 Oct 2018.
Clinical trials
- S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer
Sponsor: SWOG Cancer Research Network
- SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
Sponsor: M.D. Anderson Cancer Center
- Heat Therapy in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
Sponsor: M.D. Anderson Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Siemens Medical Solutions USA, Inc.Program year20251 payment$50,000openpaymentsdata.cms.gov ↗
- Stemline Therapeutics Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2009–2014 per NIH RePORTER. The latest:
- Non-Invasive Radio-Frequency Field Induced Therapy Destruction of Malignant Cells
Methodist Hospital Research Institute
FY2014$163,685U54CA143837 - Non-Invasive Radio-Frequency Field Induced Therapy Destruction of Malignant Cells
Methodist Hospital Research Institute
FY2013$606,330U54CA143837 - Non-Invasive Radio-Frequency Field Induced Therapy Destruction of Malignant Cells
Methodist Hospital Research Institute
FY2012$328,203U54CA143837
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients
Annals of Surgical Oncology
2004 - Long term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases
Annals of Surgical Oncology
2004 - The impact on patient management of whole-body FDG-PET scanning in patients with liver metastases from colorectal carcinoma
Journal of Clinical Oncology
2004 - Erratum: "Advances in the treatment of liver tumors" (Current Problems in Surgery (2002) vol. 39 (449-572))2002
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”